Antigen-Peptide-Transporter 2 DeficiencySymptoms, Doctors, Treatments, Advances & More
Antigen-Peptide-Transporter 2 Deficiency Overview
Learn About Antigen-Peptide-Transporter 2 Deficiency
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Hackensack University Medical Center
Jason Fisher is a General Surgeon practicing medicine in Hackensack, New Jersey. Dr. Fisher is rated as an Advanced provider by MediFind in the treatment of Antigen-Peptide-Transporter 2 Deficiency. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Antigen-Peptide-Transporter 2 Deficiency, Appendicitis, Hirschsprung Disease, Appendectomy, and Oophorectomy. Dr. Fisher is board certified in Clinical Informatics and American Board Of Surgery . Dr. Fisher is currently accepting new patients.
Mayo Clinic-Rochester
Michael Jensen is an Endocrinologist practicing medicine in Virginia Beach, Virginia. Dr. Jensen is rated as a Distinguished provider by MediFind in the treatment of Antigen-Peptide-Transporter 2 Deficiency. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Antigen-Peptide-Transporter 2 Deficiency, Obesity, Heart Failure with Preserved Ejection Fraction (HFpEF), Endoscopy, and Gastric Bypass. Dr. Jensen is currently accepting new patients.
Cleveland Clinic Main Campus
Timothy Chan is a Radiation Oncologist practicing medicine in Cleveland, Ohio. Dr. Chan is rated as an Advanced provider by MediFind in the treatment of Antigen-Peptide-Transporter 2 Deficiency. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Gliomatosis Cerebri, Astrocytoma, Glioblastoma, and Brain Tumor. Dr. Chan is board certified in American Board Of Radiology, 2009. Dr. Chan is currently accepting new patients.
Summary: This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blin...
